CellProthera raises 8.3 million euros

28 million euros to save human lives

MULHOUSE, France– CellProthera, a biotech company which offers the most advanced cell therapy for regeneration of the damaged heart muscle after myocardial infarction, announces it has raised €8,300,000 from private investors in 2016. These funds, supplements the20 million€ raised during the previous rounds, and will enable CellProthera to pursue its scientific development, complete its Phase I/IIb clinical trial in Europe and prepare its Phase III in Europe and North America.

Continue reading